Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa, Japan.
Am J Hypertens. 2011 Feb;24(2):169-74. doi: 10.1038/ajh.2010.198. Epub 2010 Sep 16.
To explore the metabolic actions of nifedipine on diabetes, we examined glucose intolerance and white adipose tissue changes in type 2 diabetic KK-A(y) mice.
Male KK-A(y) mice were treated with nifedipine (1.5 mg/kg/day in lab chow) for 5 weeks, which did not affect blood pressure or feeding of KK-A(y) mice.
After treatment with nifedipine, body weight tended to decrease and the weight of white adipose tissue was reduced. Without food restriction, nifedipine decreased plasma insulin level, while plasma glucose level tended to decrease. In oral glucose tolerance test, nifedipine suppressed the increase in glucose level after a glucose load without affecting plasma insulin concentration. Nifedipine also improved the result of insulin tolerance test. In white adipose tissue, nifedipine increased adipocyte number and the expression of peroxisome proliferator-activated receptor-γ (PPARγ) and adipocyte fatty acid-binding protein related to adipocyte differentiation. In addition, expression of adiponectin, insulin receptor, insulin receptor substrate-1, and glucose transporter type-4 was also increased by nifedipine. Nifedipine also increased the expression of NO synthase in white adipose tissue. Nifedipine did not affect expression of angiotensin II type 1 (AT₁) and type 2 (AT₂) receptors in white adipose tissue. Such changes in white adipose tissue were apparent in retroperitoneal adipose tissue. Nifedipine did not change the expression of angiotensin receptors, renin receptor, and angiotensinogen in white adipose tissue. Moreover, nifedipine attenuated nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and increased superoxide dismutase (SOD) activity in white adipose tissue.
These results suggest that nifedipine can enhance insulin sensitivity and reduce white adipose tissue, possibly related to stimulation of adipocyte differentiation.
为了探索硝苯地平对糖尿病的代谢作用,我们研究了 2 型糖尿病 KK-A(y)小鼠的葡萄糖耐量和白色脂肪组织变化。
雄性 KK-A(y)小鼠用硝苯地平(1.5mg/kg/天在实验饲料中)治疗 5 周,这不会影响 KK-A(y)小鼠的血压或摄食。
硝苯地平治疗后,体重趋于下降,白色脂肪组织重量减少。在不禁食的情况下,硝苯地平降低了血浆胰岛素水平,而血糖水平趋于下降。在口服葡萄糖耐量试验中,硝苯地平抑制了葡萄糖负荷后血糖水平的升高,而不影响血浆胰岛素浓度。硝苯地平也改善了胰岛素耐量试验的结果。在白色脂肪组织中,硝苯地平增加了脂肪细胞数量和与脂肪细胞分化相关的过氧化物酶体增殖物激活受体-γ(PPARγ)和脂肪细胞脂肪酸结合蛋白的表达。此外,硝苯地平还增加了脂肪细胞中的脂联素、胰岛素受体、胰岛素受体底物-1 和葡萄糖转运蛋白 4 的表达。硝苯地平还增加了白色脂肪组织中一氧化氮合酶的表达。硝苯地平不影响白色脂肪组织中血管紧张素 II 型 1(AT₁)和 2(AT₂)受体的表达。这些白色脂肪组织的变化在腹膜后脂肪组织中很明显。硝苯地平不改变白色脂肪组织中血管紧张素受体、肾素受体和血管紧张素原的表达。此外,硝苯地平减弱了白色脂肪组织中烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶的活性,并增加了超氧化物歧化酶(SOD)的活性。
这些结果表明,硝苯地平可以增强胰岛素敏感性并减少白色脂肪组织,这可能与刺激脂肪细胞分化有关。